Berger’s disease is a kidney condition where a specific type of immune protein, called IgA, builds up in the tiny filters of your kidneys and gradually damages them. Its medical name is IgA nephropathy, and it’s the most common form of glomerulonephritis (kidney filter inflammation) worldwide. Many people first notice it when their urine turns red or brown during a cold or sore throat. The disease ranges from mild and slow-moving to aggressive enough to cause kidney failure, with roughly one in three patients reaching that point within 20 years of diagnosis.
How Berger’s Disease Damages the Kidneys
IgA is an antibody your immune system normally produces to protect mucous membranes in your gut, lungs, and throat. In Berger’s disease, the body makes a defective version of one subtype, IgA1, that’s missing certain sugar molecules on its surface. This abnormal IgA1 circulates in the blood without causing problems on its own. The trouble starts when other antibodies recognize the defective IgA1 as foreign and latch onto it, forming large immune complexes.
These complexes are too big for the liver to clear through its normal waste-disposal route, so they end up in the kidneys instead. They lodge in the mesangium, the supportive tissue inside each kidney filter unit. Once there, the immune complexes trigger the mesangial cells to multiply, release inflammatory signals, and produce scar tissue. Over months and years, this process slowly destroys the filters, letting blood and protein leak into the urine and reducing the kidneys’ ability to do their job.
Symptoms and Early Warning Signs
The hallmark symptom is visible blood in the urine, often described as brown, red, or cola-colored. This frequently shows up within a day or two of a cold, sore throat, or other upper respiratory infection. The timing is so consistent that doctors have a name for it: synpharyngitic hematuria. For many people, this episode is the first clue anything is wrong.
Between flare-ups, the disease can be completely silent. Some people are only discovered to have it when a routine urine test picks up microscopic blood or protein they never noticed. Others develop signs of worsening kidney function over time: foamy urine (from protein leaking out), swelling in the ankles or face, high blood pressure, or fatigue. In about 5 to 10% of cases, protein loss becomes severe enough to cause nephrotic syndrome, which involves heavy swelling, very high urine protein levels, and changes in blood cholesterol.
Who Gets Berger’s Disease
Berger’s disease occurs across all populations, but rates vary dramatically by ancestry. Incidence is highest in people of East Asian descent, reaching 4.2 per 100,000 in Japan. People of European descent have intermediate rates, Hispanic populations fall somewhere in between, and people of African descent have the lowest rates, as low as 0.1 per 100,000 in some studies. Men are diagnosed more often than women. The condition is most commonly identified in the teens through the 30s, though it can appear at any age.
Genetics play a clear role. Having a family member with the disease raises your risk, and the underlying defect in IgA1 sugar molecules appears to be at least partly inherited.
How It’s Diagnosed
Blood and urine tests can raise suspicion, but the only way to confirm Berger’s disease is a kidney biopsy. A small tissue sample is examined under three types of microscopy. The defining finding is granular IgA deposits concentrated in the mesangium, visible under immunofluorescence (a technique that uses antibodies tagged with fluorescent dye). Light microscopy shows the extent of cell overgrowth and scarring, and electron microscopy reveals dense deposits in and around the filter membranes.
Pathologists score the biopsy using the Oxford Classification, sometimes called the MEST-C score. Each letter represents a feature that independently predicts how the disease will behave over time:
- M: Mesangial hypercellularity, meaning excess cell growth in the filter’s support tissue
- E: Endocapillary hypercellularity, or cell buildup inside the filter’s tiny blood vessels
- S: Segmental scarring within the filter units
- T: Tubular atrophy and surrounding tissue scarring, graded by severity
- C: Crescents, which are aggressive inflammatory formations that can rapidly worsen function
Higher scores across these categories signal a greater risk of progression. Your nephrologist uses this score alongside your blood pressure, kidney function, and protein levels to gauge how aggressively to treat.
Long-Term Outlook
Berger’s disease is chronic and, for now, has no cure. Its pace varies enormously. Some people maintain stable kidney function for decades with minimal intervention. Others progress steadily toward kidney failure. A large long-term study found that 79% of patients had not reached kidney failure or needed dialysis 10 years after biopsy, and 67% remained free of those outcomes at 20 years. That means roughly a third eventually need dialysis or a transplant over two decades.
The strongest predictors of a worse outcome are persistent protein in the urine above 1 gram per day, high blood pressure that’s hard to control, and impaired kidney function at the time of diagnosis. The biopsy findings matter too: more scarring and more crescents point toward faster decline.
Treatment Options
For years, the standard approach was to control blood pressure and reduce protein leakage using a class of blood pressure medications that protect the kidneys’ filters. These remain the foundation of treatment. The goal is to keep urine protein levels as low as possible, because protein leaking through damaged filters accelerates further damage.
Two newer therapies now target the disease more directly. Sparsentan blocks two pathways involved in kidney scarring and protein leakage. In a major clinical trial, patients taking sparsentan saw a nearly 50% reduction in urine protein, compared with about 15% for those on a standard blood pressure medication alone. Kidney function also declined more slowly over two years. Because sparsentan can affect the liver and is harmful during pregnancy, patients on it need regular liver monitoring, and those who can become pregnant must use contraception during treatment and for one month after stopping.
The other option is a targeted-release formulation of budesonide, currently the only immunosuppressive drug with full FDA approval specifically for IgA nephropathy. It delivers a steroid directly to the part of the small intestine where the defective IgA1 is produced, aiming to interrupt the disease at its source. Clinical trials showed it reduced protein leakage and slowed kidney function loss over two years. The trade-off is steroid-related side effects, including weight gain, facial puffiness, acne, and elevated blood pressure. Protein leakage also tends to return after the drug is stopped.
Diet and Daily Management
Dietary changes won’t reverse the disease, but they meaningfully support kidney health. The most impactful single change is reducing sodium intake. A lower-sodium diet helps control blood pressure, reduces swelling, and lessens the workload on damaged kidney filters. The ideal target is no more than 1,500 milligrams of sodium per day, though even cutting your current intake by 1,000 milligrams makes a measurable difference. Since the average American diet contains well over 3,000 milligrams daily, this usually means cooking more at home, reading labels, and cutting back on processed and restaurant food.
Beyond sodium, eating nutrient-rich whole foods and avoiding highly processed options supports both kidney function and overall health. As the disease advances, your nephrologist may recommend additional restrictions on protein, potassium, or phosphorus depending on your lab results. But for most people, especially earlier in the disease, keeping sodium low and eating well covers the essentials.